Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
EDQM has also issued a Certificate of Suitability for Allopurino
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Subscribe To Our Newsletter & Stay Updated